NKX2.2, PDX-1 and CDX-2 as Potential Biomarkers to Differentiate Well-Differentiated Neuroendocrine Tumors

Biomarker Research - United Kingdom
doi 10.1186/s40364-018-0129-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Well-Differentiated Neuroendocrine Carcinoma

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
1991English

Transanal Endoscopic Microsurgery for the Treatment of Well-Differentiated Rectal Neuroendocrine Tumors

Journal of the Korean Society of Coloproctology
2012English

Improved PDX and CDX Data Processing—Response

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2018English

Should Mesenteric Tumor Deposits Be Included in Staging of Well-Differentiated Small Intestine Neuroendocrine Tumors?

Modern Pathology
Forensic MedicinePathology
2014English

Two Well-Differentiated Pancreatic Neuroendocrine Tumor Mouse Models

Cell Death and Differentiation
Cell BiologyMolecular Biology
2019English

Next-Generation Sequencing Analysis and Algorithms for PDX and CDX Models

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2017English

Establishment of the First Well-Differentiated Human Pancreatic Neuroendocrine Tumor Model

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2018English

68Ga-Dotatate PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients With Well-Differentiated Neuroendocrine Tumors

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2010English

Claudin Expression in Rectal Well-Differentiated Endocrine Neoplasms (Carcinoid Tumors)

Oncology Reports
MedicineCancer ResearchOncology
1994English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy